2.425

6.01% -0.155

Pre-market: 2.42 -0.005 -0.21%

Vistagen Therapeutics Inc (VTGN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vistagen Therapeutics Inc stock is traded at $2.425, with a volume of 239.07K. It is down -6.01% in the last 24 hours and up +2.11% over the past month. Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Previous Close:

$2.58

Open:

$2.51

24h Volume:

239.07K

Relative Volume:

1.86

Market Cap:

$69.99M

Revenue:

$875.70K

Net Income/Loss:

$-39.57M

P/E Ratio:

-1.8066

EPS:

-1.3423

Net Cash Flow:

$-33.65M

1W Performance:

+0.62%

1M Performance:

+2.11%

6M Performance:

-14.31%

1Y Performance:

-37.18%

1-Day Range:

$2.31

$2.525

1-Week Range:

$2.31

$2.63

52-Week Range:

$1.90

$4.21

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name

Vistagen Therapeutics Inc

Sector

Healthcare (1166)

Industry

Biotechnology (665)

Phone

650-577-3600

Address

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

@vistagen

Next Earnings Date

2024-11-07

Latest SEC Filings

VTGN's Discussions on Twitter

Compare VTGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTGN Vistagen Therapeutics Inc	2.425	70.13M	875.70K	-39.57M	-33.65M	-1.3423
ONC Beone Medicines Ltd Adr	245.93	25.76B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	445.43	114.53B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.415	40.54M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	84.10	6.44B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.81	65.13B	14.09B	4.50B	2.96B	39.28

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-07-23	Upgrade	Jefferies	Hold → Buy
Aug-07-23	Upgrade	Maxim Group	Hold → Buy
Jul-22-22	Downgrade	Jefferies	Buy → Hold
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
May-20-21	Initiated	Robert W. Baird	Outperform
Feb-18-21	Initiated	Jefferies	Buy
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy
Feb-08-18	Reiterated	Chardan Capital Markets	Buy
Mar-28-17	Initiated	Maxim Group	Buy

View All

Vistagen Therapeutics Inc Stock (VTGN) Latest News

01:46 AM

Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial - marketscreener.com

Jun 02, 2025

Major Social Anxiety Treatment Breakthrough: Phase 3 Trial Results Coming Q4 2025What to Expect - Stock Titan

Jun 02, 2025

May 31, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat

May 31, 2025

May 28, 2025

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - sharewise

May 28, 2025

Vistagen Showcases Revolutionary Nose-to-Brain Drug Technology at Major Jefferies Healthcare Conference - Stock Titan

May 28, 2025

May 23, 2025

Breakthrough Nasal Spray Treatment Shows Promise for Depression and Social Anxiety, New Clinical Data Reveals - Stock Titan

May 23, 2025

May 11, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Renaissance Technologies LLC - MarketBeat

May 11, 2025

May 08, 2025

254,655 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Bought by Almitas Capital LLC - MarketBeat

May 08, 2025

May 06, 2025

Renaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

May 06, 2025

May 05, 2025

Form 8-KCurrent report - ADVFN

May 05, 2025

May 04, 2025

Nantahala Capital Management LLC Boosts Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

May 04, 2025

Apr 29, 2025

JPMorgan Chase & Co. Buys 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

Apr 29, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 24, 2025

JPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Apr 24, 2025

Apr 17, 2025

Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan

Apr 17, 2025

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - BioSpace

Apr 17, 2025

Apr 08, 2025

Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World

Apr 08, 2025

Apr 06, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Purchased by Blair William & Co. IL - Defense World

Apr 06, 2025

Apr 04, 2025

VTGN Stock Touches 52-Week Low at $2.21 Amid Market Challenges - Investing.com UK

Apr 04, 2025

Apr 03, 2025

VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire

Apr 03, 2025

Mental Disorder Treatment Market Set to Witness Significant - openPR.com

Apr 03, 2025

Mar 24, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat

Mar 24, 2025

Mar 21, 2025

Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR.com

Mar 21, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell? - Defense World

Mar 21, 2025

Mar 19, 2025

Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Sharewise

Mar 19, 2025

Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - StockTitan

Mar 19, 2025

Mar 14, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat

Mar 14, 2025

Mar 12, 2025